tradmap

AVTR Avantor, Inc.

$15.60 -2.86%

Data as of close

Healthcare · Laboratory Analytical Instruments

Avantor, Inc. (AVTR) is a healthcare company in the Laboratory Analytical Instruments industry, with a market capitalization of $10.6 billion. Shares last traded at $15.60, 10.6% below their 52-week high. Over the past year the stock is up 41.3%. AVTR trades at a price-to-earnings ratio of 31.35, below the Laboratory Analytical Instruments median of 38.26. Net profit margin is 5.1%, above the peer median of 1.9%. Revenue declined 3.4% year over year.

Market Cap
$10.6B
Shares Out
677.6M
EPS (TTM)
$0.50
P/E (TTM)*
31.35
P/S Ratio
1.59
P/B Ratio
1.81
Dividend / Share
—
Dividend Yield
—
52-Week High
$17.45
52-Week Low
$7.27
Volume (venue)
646,686
Avg Vol (3m, venue)
722,072.476

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-9.75%
1M
+1.73%
3M
+14.04%
6M
+95.24%
YTD
+36.13%
1Y
+41.30%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
43.02
SMA (50)
$15.52
SMA (200)
$11.21
Price vs SMA50
+0.55%
Price vs SMA200
+39.13%
ATR (14)
$0.52

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$6.6B
Net Income
$337M
Gross Margin
31.6%
Operating Margin
7.3%
Net Margin
5.1%
Return on Equity
5.8%
Return on Assets
2.9%
Current Ratio
1.89
Debt / Equity
0.63
Revenue Growth (YoY)
-3.4%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 $0.30 2026-10-28
Q2 2026 $0.06 2026-07-29
Q1 2026 $0.06 2026-04-29
Q4 2025 (derived) $0.08 2026-02-11
FY 2025 -$0.78 2026-02-11
Q3 2025 -$1.04 2025-10-29

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Laboratory Analytical Instruments peers

AVTR vs 14 industry peers (Laboratory Analytical Instruments), by market cap. Data as of close

P/E vs peers
31.35 / 38.26 med
-18% discount
P/S vs peers
1.59 / 4.80 med
-67% discount
Net margin vs peers
5.1% / 1.9% med
above median
1–14 of 14
AAgilent Technologies$48.5B33.686.5819.5%-1.62%
WATWaters Corporation$44.2B68.719.5113.8%-2.86%
ILMNIllumina, Inc.$34.2B38.267.5519.7%-4.10%
MTDMettler Toledo$33.6B37.148.1421.9%+0.17%
RVTYRevvity$16.9B71.265.818.2%-3.38%
AVTRAvantor, Inc.$10.6B31.351.595.1%-2.86%
BIOBio-Rad Laboratories, Inc.$9.8B44.033.788.6%-1.57%
BRKRBruker Corp$8.5B—2.42-2.0%-2.48%
TXG10x Genomics, Inc.$8.0B—13.01-12.2%-12.14%
ALMRAlamar Biosciences, Inc.$2.0B———-5.48%
CTKBCytek Biosciences, Inc.$751M—3.63-32.2%-5.56%
PACBPacific Biosciences Of California, Inc.$727M———-10.34%
MASS908 Devices Inc.$421M—6.92-57.0%-9.26%
NAUTNautilus Biotechnology, Inc.$302M———-13.50%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.